Acamprol 333mg Tablet (Acamprosate)

Acamprol 333mg Tablet is used to help people with alcohol dependence maintain abstinence after they have stopped drinking alcohol.

It contains acamprosate 333 mg and is generally used after alcohol withdrawal has been completed and the patient has achieved abstinence.

Acamprol does not treat acute alcohol withdrawal symptoms, such as withdrawal-related tremors or seizures. It should form part of a broader recovery program that includes counseling or psychosocial support.

The main benefit of Acamprol is helping appropriate patients maintain alcohol abstinence during recovery from alcohol dependence.

After long-term alcohol use stops, changes in brain signaling may contribute to difficulty remaining abstinent. Acamprosate is intended to support ongoing abstinence while the patient continues a comprehensive alcohol-dependence treatment program.

It is not a standalone cure for alcohol dependence and works best as part of structured medical and psychosocial care.

Acamprol should be taken exactly as prescribed by a healthcare professional and the enteric-coated tablets should be swallowed whole.

Current U.S. acamprosate labeling lists a usual adult regimen of 666 mg—two 333 mg tablets—three times daily, although individual dosing can differ, particularly in people with kidney impairment. Patients should not change the dose themselves.

Acamprosate may be dosed without regard to food; taking it with meals can provide a convenient regular schedule for people who eat three meals daily. Do not chew or crush enteric-coated tablets.

The exact mechanism of acamprosate is not completely understood, but it appears to influence brain signaling involved in adaptation after long-term alcohol exposure.

Chronic alcohol consumption can affect the balance between excitatory and inhibitory neurotransmitter systems.

Evidence suggests acamprosate may interact with glutamate and GABA-related neurotransmission, potentially helping stabilize this altered signaling after a person stops drinking.

Therefore, I recommend not keeping your current page's definitive statement that it simply “blocks NMDA receptors and activates GABA-A receptors.” Your existing page currently uses that wording. Official prescribing information is more cautious and states that the mechanism is not completely understood.

Diarrhea is one of the commonly reported side effects of acamprosate, although other gastrointestinal and nervous-system effects may occur.

Possible reactions include diarrhea, nausea, abdominal discomfort, flatulence, dizziness, dry mouth, itching, sweating, anxiety and sleep disturbance.

Patients should contact a healthcare professional if symptoms become persistent or severe. Current prescribing information also advises monitoring for new or worsening depression or suicidal thoughts. Acamprosate requires dose reduction with moderate renal impairment and is contraindicated in severe renal impairment.